About 75% of upper tract #urothelial carcinoma (#UTUC) cases happen in men. Raising awareness can lead to early diagnosis, better outcomes, and a stronger support network for those impacted. #MensHealthMonth

Hear our CEO, Liz Barrett, explain what the ENVISION Trial results and benefits of gel-based technology potentially mean for LG-IR-NMIBC patients in an interview with BiotechTV.

At UroGen, we are passionate about fundamentally changing the way patients are treated for urologic cancers. We are driven by the precious moments and possibilities we preserve for patients. Learn how we work together to develop life-changing solutions for patients:

At UroGen, our passion for patients defines who we are. We focus on fundamentally changing the way patients are treated for urologic cancers.

We’re excited to be at the World Conference on Genitourinary Cancers in New York! Drop by Booth #17 to discuss #bladdercancer and our latest pipeline updates. See you there!

Our President & CEO, Liz Barrett, is on Forbes’ annual #ForbesOver50 list! Read about the impact she’s making at UroGen and within our industry. #knowyourvalue Maggie McGrath

We’ll be announcing UroGen Pharma's Q2 2024 financial results during a live webcast on August 13 at 10:00 AM ET. Click below to learn more. $URGN

As a proud sponsor of the annual @bladdercancerUS Think Tank, we look forward to presenting a research update and engaging in discussions on #bladdercancer research and innovation to improve patient care.

Today, we shared our Q2 2024 financial results. Click to access the recorded, live audio webcast. $URGN

Today we announced the submission of the completed New Drug Application to the U.S. FDA, for UGN-102, our investigational treatment in development for low-grade intermediate-risk non-muscle invasive #bladdercancer. $URGN

Despite its prevalence, there are currently no drugs approved by the FDA for the treatment of low-grade, intermediate-risk non-muscle-invasive #bladdercancer (LG-IR-NMIBC). The availability of more options could help patients better manage their disease.

Members of our management team will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9th, 2024 at 9:00am ET.

We are excited to announce UroGen has received a patent allowance for our next-generation mitomycin-based products for patients with low-grade intermediate-risk non-muscle invasive bladder cancer and low-grade upper tract urothelial cancer, respectively.

Members of our management team will participate in a fireside chat at the Cantor Global Healthcare Conference in New York on September 17 at 3:40 p.m. ET.

Low-grade upper tract urothelial cancer (#UTUC) is a rare cancer that occurs in the lining of the kidneys and ureters. UroGen is a partner in treating LG-UTUC and is committed to improving patients’ lives. #UrologyAwarenessMonth

At UroGen, we are committed to elevating options for people living with urological cancers. We’re proud to support TheUrologyFoundation in spreading awareness of men’s urology health this month. #UAM24 #UrologyAwarenessMonth

There are an estimated 60,000 recurrences annually among patients with low-grade intermediate-risk non-muscle-invasive #BladderCancer (LG-IR-NMIBC). We believe patients deserve more treatment options. #UrologyAwarenessMonth

Current treatments for low-grade upper tract urothelial cancer (LG-UTUC) have high recurrence rates. We’re dedicated to researching and developing more treatment options for LG-UTUC patients and those with urological cancers. #UrologyAwarenessMonth

We are pleased to announce the first patient has been dosed in our Phase 3 UTOPIA study, a clinical trial evaluating our investigational drug UGN-103, in patients with low-grade intermediate-risk non-muscle invasive #bladdercancer.

We’re excited to welcome Chris Degnan as UroGen’s new Chief Financial Officer. With broad and extensive experience in financial strategy at publicly traded biotechs, Chris will help lead UroGen’s next phase of growth.